Picture of Alliance Pharma logo

APH Alliance Pharma News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

REG - Alliance Pharma PLC - Senior Management and Board Update

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230112:nRSL4606Ma&default-theme=true

RNS Number : 4606M  Alliance Pharma PLC  12 January 2023

 

 For immediate release  12 January 2023

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Senior Management and Board Update

Appointment of COO to drive strategic growth in consumer healthcare

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
the appointment of a Chief Operating Officer to strengthen the executive team
and Board of Directors, and to support the delivery of the Company's growth
strategy which is focused on consumer health. The Group also provides an
update on the return to the business of Peter Butterfield, the Chief Executive
Officer.

 

Chief Operating Officer ("COO")

Jeyan Heper will join Alliance as COO and Board member on 1 February 2023.
Jeyan has a strong track record of strategic leadership in the international
consumer health market, overseeing a number of global programs and driving
growth in flagship brands. In his career spanning more than 24 years Jeyan has
held senior executive roles in brand management at Procter & Gamble and
marketing at Danone Group. In addition, Jeyan was President and General
Manager of Ansell's sexual wellness global business before it was spun-out to
become Lifestyles Healthcare, a private equity/pharma-owned company where
Jeyan became CEO.

 

During his tenure as CEO at Lifestyles Healthcare, Jeyan delivered significant
growth through market and category expansion, building a strong e-commerce
platform in China and the US, and improving operational effectiveness. Most
recently, Jeyan worked as Head of Global Transformation at British American
Tobacco ("BAT") leading the development and execution of the strategy to
broaden the company's reach into non-nicotine consumer products. Following
BAT's minority investment in NASDAQ-listed Organigram Inc., Jeyan became a
member of the Organigram board.

 

The role of COO will bolster the Group's operational capabilities, identify
growth opportunities, and drive further the Company's strategy to expand its
consumer health presence.

 

Update on Chief Executive Officer ("CEO")

Peter Butterfield, CEO, is expected to commence his return to the business in
Q1 2023 on a phased basis. To assist Peter's return and to strengthen further
the executive team, the Board has decided to appoint an interim CEO who is
expected to join the Board. The interim CEO will focus primarily on strategic
delivery and external stakeholder engagement, is expected to remain with
Alliance throughout the upcoming appeal hearing at the Competition Appeal
Tribunal, which is scheduled to commence on 5 June 2023, and will hand-back to
Peter thereafter. The recruitment process is well underway and a further
update will be provided in due course.

 

David Cook, Chair of Alliance, said:

"I am delighted that Jeyan is joining Alliance. The Company has grown and
developed significantly since I became Chair, building an international
footprint with a strong portfolio of consumer healthcare brands. The
appointment of a COO will ensure that the organisational structure is
appropriate for the future of the business. Jeyan will bring significant
additional expertise from the global consumer healthcare sector to keep the
Company well positioned to deliver continued growth over the longer term.

 

"We very much look forward to welcoming Peter back to Alliance, the Board
believes that the appointment of the interim CEO will help to make his return
seamless."

Save as disclosed below, the Company confirms that there are no further
disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two
of the AIM Rules for Companies in respect of Jeyan Heper's appointment to the
Alliance Board.

 

Mr Jeyan Heper, aged 49, does not currently hold any directorships but has
held the following in the past five years:

 

 Directorships in the past five years:  Lifestyles Healthcare Pte Ltd

                                        Organigram Holdings Inc (Canada)

                                        Sxwell UK Limited (UK)

                                        Unimil Sp. z o.o20 (Poland)

                                        Lifestyles Europe SAS (France)

                                        Ansell Healthcare Europe NV (Belgium)

                                        SXWell Belgium BV (Belgium)

 

Mr Heper does not hold any ordinary shares of 1 pence each in the Company.

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited                                                  + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 Investec Bank plc                                                         + 44 (0)20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASFIEFFEDSEFF

Recent news on Alliance Pharma

See all news